Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEOPA + paracetamol
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous, Oral
01
Overview
MEOPA + paracetamol is a combination therapy consisting of MEOPA (a nitrous oxide and oxygen mixture) and paracetamol (acetaminophen). This combination is used for pain management, particularly in acute settings. MEOPA provides rapid-onset analgesia through its nitrous oxide component, while paracetamol offers longer-lasting pain relief. The combination has been studied for use in pre-hospital settings due to its ease of administration.
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on MEOPA + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEOPA + paracetamol.